Characterization of and osteoarthritis susceptibility in ADAMTS‐4–knockout mice
Open Access
- 5 August 2004
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 50 (8) , 2547-2558
- https://doi.org/10.1002/art.20558
Abstract
Objective To determine the importance of the enzymatic activity of ADAMTS‐4 in normal growth and development and to evaluate the role of ADAMTS‐4 in the progression of osteoarthritis (OA). Methods We generated catalytic domain–deleted ADAMTS‐4–transgenic mice and performed extensive gross and histologic analyses of various organs. The mice were challenged by surgical induction of joint instability leading to OA, to determine the importance of the enzymatic activity of ADAMTS‐4 in the progression of the disease. The response of wild‐type (WT) and ADAMTS‐4–knockout (ADAMTS‐4–KO) articular cartilage to interleukin‐1 and retinoic acid challenge in vitro was also evaluated. Results ADAMTS‐4–KO mice up to 1 year of age exhibited no gross or histologic abnormalities in 36 tissue sites examined. Despite evidence of ADAMTS‐4 expression and activity in growth plates of WT mice, catalytic silencing of this proteinase caused no abnormalities in skeletal development, growth, or remodeling. There was no effect of ADAMTS‐4 knockout on the progression or severity of OA 4 weeks or 8 weeks after surgical induction of joint instability. Enzymatic cleavage of aggrecan at the TEGE373–374ARGS site was clearly evident after exposure of articular cartilage from ADAMTS‐4–KO mice to inflammatory cytokines. Conclusion Although expression of the ADAMTS‐4 gene has been found in many tissues throughout the body, deletion of enzymatic activity did not appear to have any effect on normal growth and physiology. Our study provides evidence that ADAMTS‐4 is the primary aggrecanase in murine growth plates; however, deletion of its enzymatic activity did not affect normal long bone remodeling. Our results also lead to the hypothesis that, in the mouse, ADAMTS‐4 is not the primary enzyme responsible for aggrecan degradation at the TEGE373–374ARGS site. The elucidation of the relative importance of ADAMTS‐4 in the pathologic process of human OA will require examination of human OA tissues and evidence of disease modification in patients following therapeutic intervention.Keywords
This publication has 41 references indexed in Scilit:
- Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitroArthritis & Rheumatism, 2002
- Expression and Regulation of Aggrecanase in Arthritis: The Role of TGF-βThe Journal of Immunology, 2002
- Cyclosporin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilageArthritis & Rheumatism, 2002
- The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradationOsteoarthritis and Cartilage, 2001
- The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritisCurrent Opinion in Pharmacology, 2001
- Sites of Aggrecan Cleavage by Recombinant Human Aggrecanase-1 (ADAMTS-4)Journal of Biological Chemistry, 2000
- n-3 Fatty Acids Specifically Modulate Catabolic Factors Involved in Articular Cartilage DegradationJournal of Biological Chemistry, 2000
- Cloning and Characterization of ADAMTS11 , an Aggrecanase from the ADAMTS FamilyJournal of Biological Chemistry, 1999
- Purification and Cloning of Aggrecanase-1: A Member of the ADAMTS Family of ProteinsScience, 1999
- The structure of aggrecan fragments in human synovial fluid. evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritisArthritis & Rheumatism, 1993